NCT06573736View on ClinicalTrials.gov

Stockholm3 Use Prior to MRI for Prostate Cancer Detection in a Clinical Care Pathway: a Multi-centered Validation

Not yet recruitingOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 31, 2025

Conditions

Prostate Cancer

Interventions

DIAGNOSTIC_TEST

Stockholm3

Stockholm3 combines protein markers tPSA, fPSA, KLK2, PSP94 and GDF15, genetic markers and clinical data to estimate risk for clinically significant prostate cancer.

All Listed Sponsors

lead

Karolinska Institutet

OTHER